Navigation Links
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Date:11/22/2013

#160;These safety findings were consistent with those observed in prior investigational studies with sarilumab."Irreversible joint damage can be a consequence for patients suffering from rheumatoid arthritis, and this is accompanied by reduced physical function in these patients," said Tanya M. Momtahen, M.S., Sarilumab Global Project Head, Sanofi.  "This remains a major concern for rheumatoid arthritis patients.  We are encouraged by these Phase 3 results and the impact sarilumab demonstrated on inhibition of progression of structural damage assessed radiographically in this study."

Additional analyses of efficacy and safety data from the SARIL-RA-MOBILITY study will be presented at a future medical conference.

About Sarilumab
Sarilumab (REGN88/SAR153191) is the first fully-human monoclonal antibody directed against the IL-6 receptor (IL-6R).  Sarilumab is a subcutaneously delivered inhibitor of IL-6 signaling, which binds with high affinity to the IL-6 receptor.  It blocks the binding of IL-6 to its receptor and interrupts the resultant cytokine-mediated inflammatory signaling.  Sarilumab was developed using Regeneron's VelocImmune® antibody technology.

The investigational agent described above is currently under clinical development and its safety and efficacy have not been fully evaluated by any regulatory authority.

About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs.  Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.  Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals
Regeneron is a leading science
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics ... MA is revolutionizing spinal cord injury (SCI) ... been shown to outperform in tissue regrowth in the ... scaffold.  Made from an FDA approved polymer, the scaffold ... it harmless to the human body. NVIV has recently ...
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
(Date:10/22/2014)... -- Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing ... for cancer, is designed for injection into solid tumors ... focus is on melanoma, breast cancer and cancers of ... PV-10 as a therapy for metastatic melanoma, and of ... psoriasis. This summer, the Company signed ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... 8 , - Glivec(R) (imatinib) ... KIT (CD117)-Positive Gastrointestinal Stromal Tumours,(GIST), who are at Significant Risk ... - Use of Glivec(R) After Surgery Significantly Reduces Risk ... After Surgery, 50% of patients Will Experience Their,Cancer Returning Within ...
... guidance regarding strategic transaction processSAN DIEGO, May 7 ... ANX ) today announced results from its bioequivalence ... determined to have comparable overall safety as Taxotere(R), ... groups in severe toxicities. However, pharmacokinetic equivalence, ...
Cached Medicine Technology:Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 2Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 3Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 4Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 5Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 6ADVENTRX Announces Results From ANX-514 Bioequivalence Study 2ADVENTRX Announces Results From ANX-514 Bioequivalence Study 3ADVENTRX Announces Results From ANX-514 Bioequivalence Study 4ADVENTRX Announces Results From ANX-514 Bioequivalence Study 5
(Date:10/25/2014)... Interrupting blood supply to an arm or a leg before ... surgery, according to a new study. "During heart ... heart to be able to operate on it. After some ... to produce energy because it doesn,t get oxygen. When we ... as an arm or a leg, the body prepares for ...
(Date:10/25/2014)... News) -- Not getting the right amount of sleep ... study suggests. Those who sleep less or more ... may be more prone to developing the chronic condition, ... study authors concluded that duration and quality of sleep ... inflammatory bowel diseases. "Both short and long durations ...
(Date:10/25/2014)... large influx of international aid is needed, and soon, ... of deaths from the widening Ebola crisis, a team ... specially designed mathematical model, the researchers looked at the ... populated county of hard-hit Liberia -- Montserrado County, home ... said that if international aid isn,t delivered to Liberia ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... developed that spot increased risks for certain cancers, one might ... screened. But a new study suggests that, at least ... found out their genes doubled their risk of colon cancer ... get screened. "It didn,t make any difference, not at ...
(Date:10/22/2014)... Pennsylvania (PRWEB) October 22, 2014 At ... and uncertainty among parents and athletes at all levels, ... working to change the current discussion where two powerful ... are evidence-based therapies that result in full recoveries every ... to one based in fact and research, UPMC and ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... S. Department of Health and Human Services (HHS) and ... launch National Infant Immunization Week (NIIW) with events// April ... are expected to participate in NIIW by sponsoring activities ... ,CDC and HHS will collaborate with state ...
... Brodie Campbell are still in shock and grief over the ... have reportedly brought in grief counselors to help students deal ... student at his school- Dr. Charles Best Secondary School in ... has now confirmed the reason of death as bacterial meningitis. ...
... losing its forests to over-exploitation, will get help in ... which signed up the// country as a member this ... Analysis (IIASA), Austria - a non-governmental research organization that ... the context of global change - has said it ...
... Institute of Medical Sciences (AIIMS) has developed artificial testis, ... genitals.// ,Doctors at the premier referral hospital ... such problems, achieving 100 percent success. ,"We ... patients with not a single case of rejection. From ...
... scam burst into the open in Paris, Dr. Brian ... three months by the// Californian state authorities. ... Area Laboratory Co-Operative that allegedly provided steroids to top ... five years' probation and ordered to undergo a psychiatric ...
... too serious a matter to be left in the hands of ... the care of labour department officials. At least such// seems to ... that agencies like the Occupational Safety and Health Administration ... than with the safety of the workers themselves. ...
Cached Medicine News:Health News:National Infant Immunization Week Urges Parents to Vaccinate On Time 2Health News:India to Protect Its Forests With the Aid of Austrian NGO 2Health News:Artificial Testis Developed by AIIMS a Boon to Suffering Patients 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 3Health News:Overseeing Agency Indifferent to Workplace Safety in US 2
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Headlight module is mounted on UltraLite Plus headband or sweatband....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
Medicine Products: